Genmab A/S

Healthcare

NASDAQ:GMAB · NASDAQ Global Select

Market Cap $15.40B Beta 0.68 P/E (TTM) 18.7

$25.08 -0.63%

-$0.16 today

52W Low $20.23High $35.43

Vol 1.11M · Avg 1.80M

EPS (TTM)$13.36

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+9.90%

Period High

$35.34

Period Low

$20.30

Latest

$25.08

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Illumina, Inc.

NASDAQ:ILMN

$24.35B

Royalty Pharma plc

NASDAQ:RPRX

$23.60B

United Therapeutics Corporation

NASDAQ:UTHR

$23.17B

Quest Diagnostics Incorporated

NYSE:DGX

$22.48B

Incyte Corporation

NASDAQ:INCY

$21.68B

Roivant Sciences Ltd.

NASDAQ:ROIV

$21.61B

Zimmer Biomet Holdings, Inc.

NYSE:ZBH

$17.13B

Tenet Healthcare Corporation

NYSE:THC

$15.04B

Exelixis, Inc.

NASDAQ:EXEL

$13.35B

Summit Therapeutics Inc.

NASDAQ:SMMT

$10.86B

What is the latest GMAB filing?

The latest filing shown is 6-K dated Jun 11, 2026.

How many recent filings does GMAB have?

Intrinsic Alpha currently shows 20 recent filings for GMAB.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.